Live news related to IPSEN stock (FR0010259150): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on IPSEN mainly cover M&A activity, analyst notes et share price moves. The stock trades at €158,40 on Euronext Paris, down 2,82% at the last update. This page lists the articles published on IPSEN stock to track the share price, company announcements and any item likely to influence market perception.
On July 22, 2026, Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a Swiss biotechnology company. This acquisition grants th…
In mid-morning trading in Paris, the biopharmaceutical company continues its decline in a downward-trending Parisian market. The stock is erasing some…
The biopharmaceutical laboratory experiences a sharp decline in the morning, following a major clinical announcement about its botulinum toxin. The st…
On July 9, 2026, Ipsen announced positive Phase III results for Dysport in the prevention of both episodic and chronic migraine, becoming the first la…
The biopharmaceutical company stands out in the late Paris session, continuing an upward trend that started several weeks ago. The stock is testing a …
French pharmaceutical company Ipsen announced on Wednesday the acquisition of Swiss biotech firm Memo Therapeutics AG to bolster its rare disease port…
In early afternoon trading, the French biopharmaceutical company stands out in a sluggish Paris market. The stock continues its upward trend from rece…
The biopharmaceutical group Ipsen announced on Monday the acquisition of biotech firm Kartos Therapeutics for an initial amount of $450M. This move al…
The French biopharmaceutical company stands out sharply at mid-session in a downward trending Parisian market. The stock approaches its technical resi…
The French biopharmaceutical company is down in early afternoon trading in a declining Parisian market. The stock is erasing some of its recent reboun…
